Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.

Clinical drug investigation - 1 Jan 2015

López Aspiroz Elena, Cabrera Figueroa Salvador Enrique, Iglesias Gómez Alicia, Valverde Merino María Paz, Domínguez-Gil Hurlé Alfonso

Abstract excerpt

Cytochrome P450 (CYP) 3A4 has been considered to be the most important enzyme system for metabolism of lopinavir/ritonavir (LPV/r), a widely used HIV protease inhibitor (PI) recommended during pregnancy. Herein we present a clinical case of a pregnant HIV-infected woman who was taking standard doses of LPV/r, 400/100 mg twice daily. The trough plasma concentrations for LPV were fourfold above that recommended for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Polymorphism, Single Nucleotide

Share to Pregnancy

Share to Pregnancy Complications, Infectious

Source

Identifiers

PMID: 25391550
DOI: 10.1007/s40261-014-0245-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.PMID 25391550Read ↗

Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.Semantic proximity Read ↗

Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring.Semantic proximity Read ↗

Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.Semantic proximity Read ↗

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Semantic proximity Read ↗

Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.Semantic proximity Read ↗

Pregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 WomenSemantic proximity Read ↗

Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.Semantic proximity Read ↗

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.Semantic proximity Read ↗

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.Semantic proximity Read ↗

CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.Semantic proximity Read ↗

Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.Semantic proximity Read ↗

Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.